Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study

AIMS: Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso‐enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liver, a potential drug–drug interaction may occur. I...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Belderbos, Bodine P.S., Hussaarts, Koen G.A.M., van Harten, Leonie J., Oomen‐de Hoop, Esther, de Bruijn, Peter, Hamberg, Paul, van Alphen, Robbert J., Haberkorn, Brigitte C.M., Lolkema, Martijn P., de Wit, Ronald, van Soest, Robert J., Mathijssen, Ron H.J.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6475678/
https://ncbi.nlm.nih.gov/pubmed/30737835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13889
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky